Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: 148 and share price

148 and share price

posted on Jan 01, 2008 02:30PM

I am hopeful that TPL will answer the USPTO's questions concerning prior art and the 148 (just like the 584).  However, like milestone pointed out, this could take some time.  Only one claim was questioned with the 584 (29).  It seemed to render the patent useless until the situation is resolved.

My concern is whether or not companies will still want to license the MMP in the near future until we find out what strength is left.  Or, will we have to continue to license at a discount. 

I am a little nervous.  I remember how fast sp dropped after the announcement of the PTO's non-final judgement rejection of claim 29 from 584.

Please tell me it is going to be alright:)

Share
New Message
Please login to post a reply